ArticleNature communications2015
Microscale insights into pneumococcal antibiotic mutant selection windows.
Article in Nature communications, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Global trends and research profile of antibiotic heteroresistance: a bibliometric and visual analysis.Frontiers in microbiology · 2026Pooled it
- Beyond susceptibility results: understanding the clinical and diagnostic burden of bacterial heteroresistance.Molecular biology reports · 2026Review
- Genome contamination may lead to an overestimation of horizontal gene transfer inferences.Nature communications · 2026Article
- Molecular characterization of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae susceptible to delafloxacin.The Journal of antimicrobial chemotherapy · 2025Article
- The diverse phenotypic and mutational landscape induced by fluoroquinolone treatment.mSystems · 2025Article
- Inducible Mega-Mediated Macrolide Resistance Confers Heteroresistance in Streptococcus pneumoniae.Antimicrobial agents and chemotherapy · 2023Article
- The Phenomenon of Antibiotic Resistance in the Polar Regions: An Overview of the Global Problem.Infection and drug resistance · 2023Review
- Amoxicillin-resistanteLife · 2022Article
- Nanobiotic formulations as promising advances for combating MRSA resistance: susceptibilities and post-antibiotic effects of clindamycin, doxycycline, and linezolid.RSC advances · 2021Article
- Exploration of Bacterial Bottlenecks and Streptococcus pneumoniae Pathogenesis by CRISPRi-Seq.Cell host & microbe · 2021Article
- Stochastic bacterial population dynamics restrict the establishment of antibiotic resistance from single cells.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Antibiotic Resistance and Epigenetics: More to It than Meets the Eye.Antimicrobial agents and chemotherapy · 2020Review
- A Rapid and Low-Cost Pathogen Detection Platform by Using a Molecular Agglutination Assay.ACS central science · 2018Article
- Beyond the bulk: disclosing the life of single microbial cells.FEMS microbiology reviews · 2017Review
- Quorum sensing integrates environmental cues, cell density and cell history to control bacterial competence.Nature communications · 2017Article
- Transcriptional Repressor PtvR Regulates Phenotypic Tolerance to Vancomycin in Streptococcus pneumoniae.Journal of bacteriology · 2017Article
- High-throughput CRISPRi phenotyping identifies new essential genes inMolecular systems biology · 2017Article
- Collective Resistance in Microbial Communities by Intracellular Antibiotic Deactivation.PLoS biology · 2016Article
- The biofilm inhibitor Carolacton inhibits planktonic growth of virulent pneumococci via a conserved target.Scientific reports · 2016Article
- β-Lactam Resistance Mechanisms: Gram-Positive Bacteria and Mycobacterium tuberculosis.Cold Spring Harbor perspectives in medicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The human pathogen Streptococcus pneumoniae shows alarming rates of antibiotic resistance emergence. The basic requirements for de novo resistance emergence are poorly understood in the pneumococcus. Here we systematically analyse the impact of antibiotics on S. pneumoniae at concentrations that inhibit wild type cells, that is, within the mutant selection window. We identify discrete growth-inhibition profiles for bacteriostatic and bactericidal compounds, providing a predictive framework for distinction between the two classifications. Cells treated with bacteriostatic agents show continued gene expression activity, and real-time mutation assays link this activity to the development of genotypic resistance. Time-lapse microscopy reveals that antibiotic-susceptible pneumococci display remarkable growth and death bistability patterns in response to many antibiotics. We furthermore capture the rise of subpopulations with decreased susceptibility towards cell wall synthesis inhibitors (heteroresisters). We show that this phenomenon is epigenetically inherited, and that heteroresistance potentiates the accumulation of genotypic resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.